Heart failure and transplantation with Dr Ileana Piña

 
 

Heart failure and transplantation with Dr Ileana Piña

  • Hispanics and CVD: Country of Origin Matters   Hispanic, Latino -- the lingo and migratory patterns have changed over time, which is why clinicians should not assume that all patients share the same risk profiles, cautions Ileana Piña, MD.
  • SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context   Dr Ileana Piña asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.
  • Cookbook Medicine Won't Cut It With New Drugs for HFrEF   The plethora of new drugs means one size will not fit all patients with HFrEF. Clinicians will have to tailor their strategies, says Ileana Pina, MD.
  • Clinical Trials and the COVID-19 Conundrum   The pandemic has critically altered current clinical research. Dr Ileana Pina implores researchers to work together and 'not stop all the good work that is being done.'
  • VICTORIA PIs See Vericiguat as 'A Win' for High-Risk HFrEF   Ileana Piña gets the details on vericiguat, an investigational guanylate cyclase stimulator that may open up a new treatment pathway for high-risk heart failure.
  • Is Hyperkalemia Always Bad in Patients With HF?   Dr Ileana Piña discusses facilitating RAAS inhibitors with potassium binders for patients with renal dysfunction.
  • Do More HF Drugs Make It the Best or the Worst of Times?   New HF treatment regimens keep piling new drugs onto the old ones, making it less likely that patients will be able to adhere to the regimen, says Dr Ileana Piña.
  • Controversies in Cardiogenic Shock   Dr Ileana Piña discusses controversies surrounding cardiogenic shock, including data presented at the AHA Scientific Sessions 2019.
  • Making Room for New Drugs for Heart Failure   Drs Ileana Piña and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.
  • PROVE-HF Cracks the 'Holy Grail' of Cardiac Remodeling in HFrEF   Ileana Piña, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.
  • PARAGON-HF: Is There a Role for the ARNI in HFpEF?   Ileana Piña quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients with HFpEF, including exploratory subgroup analyses and use of mineralocorticoid-receptor antagonists.
  • Do We Need to Rethink Acute Heart Failure?   Patients with acute heart failure may comprise more than one single group, says Dr Piña.
  • 'Think Twice' Before Stopping Heart Failure Meds   Positive effects can be lost and patient outcomes adversely affected if heart failure drugs are stopped. Dr Pina reviews new evidence.
  • Hopeful Heart: Hope for Improving QoL in Depressed HF Patients   'Depression kills,' says Bruce Rollman, MD, the lead author of the Hopeful Heart study. Screening can identify HF patients at risk for depression and improve outcomes.
  • SGLT2 Inhibitors to Prevent HF: Time to Get More Proactive?   Drs Pi?a and Butler discuss the accumulating 'consistent' data regarding SGLT2 inhibitors for prevention of heart failure in patients with diabetes.
  • Sodium Restriction in HF: Take It With a Grain of Salt?   Despite wide acceptance, evidence to support low-sodium diets is lacking. Until we know more, keep dietary recommendations simple, says Ileana Piña, MD.
  • Does PIONEER-HF Warrant Acute HF Indication for ARNI?   Drs Pina and Butler discuss the new findings of PIONEER-HF, a trial evaluating angiotensin-neprilysin inhibition in acute heart failure.
  • PIONEER: A Role for ARNI in Stabilized Acute HF?   Sacubitril/valsartan (Entresto) was studied in patients with acute decompensated heart failure in the PIONEER HF Trial. Dr Pi?a gets the details from lead investigator Eric Velazquez.
  • Teaming Up to Prevent Heart Disease in People With Diabetes   The American Heart Association and American Diabetes Association are collaborating to improve cardiovascular care of patients with diabetes. Drs Ileana Piña and Stacey Rosen discuss the initiative.
  • Coronary Microvascular Dysfunction: Common Finding in HFpEF   Dr Ileana Pi?a discusses coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction with PROMIS-HFpEF investigator Dr Carolyn Lam.